HBV mutation literature information.


  Biochemical and Structural Properties of Entecavir-Resistant Hepatitis B Virus Polymerase with L180M/M204V Mutations.
 PMID: 27313669       2016       Experimental and therapeutic medicine
Discussion: A previous study reported that LAM-resistant variants, rtM204I/V and rtL180 M, were suppressed, but ADV-resistant variant rtA181 V/T emerged after 13-19 months of LAM-ADV sequential monotherapy.
Discussion: The results of the present study demonstrated that replication of ADV-resistant variants, rtA181T/V and rtN236T, was inhibited by combination therapy with ADV-ETV, whereas LAM-resistant rtL180 M and rtM204I/V were persistent during 30-41 months of combination the


  Biological characteristics comparison of HBV rtA181T mutants with truncated or substituted HBsAg expression in vitro and in vivo model systems.
 PMID: 27976732       2016       Scientific reports
Abstract: As the polymerase gene completely overlaps with the envelope (S) gene, HBV rtA181T mutation also carries sW172 mutations.
Abstract: In animal experiments, we were amazed to find that viral replication in rtA181T/sW172* mutant increased and maintained significantly longer than that in rtA181T/sW172L mutant, while no significant difference was observed between rtA181T/s PMID: 28139541       2016       The Indian journal of medical research
Result: VBT on ADV monotherapy was noted in eight patients (33.3%), rtA181T and rtN236T mutants were detected alone in 8.1 and 8.3 per cent in the conserved regions B and D of rt region of HBV polymerase gene, respectively.


  Nucleos(t)ide analogues causes HBV S gene mutations and carcinogenesis.
 PMID: 27919846       2016       Hepatobiliary & pancreatic diseases international
1Abstract: DATA SOURCES: PubMed and Web of Science were searched using terms: ""hepatitis B virus"", ""HBV drug resistance mutation"", ""HBV surface protein"", ""HBV truncation"", ""hepatocellular carcinoma"", ""rtA181T/sW172*"", ""rtM204I/sW196*"", ""rtV191I/sW182*"", and relevant articles published in English in the past decades were reviewed."
Abstract: RESULTS: The rtA181T/s


  Hepatocarcinogenesis in transgenic mice carrying hepatitis B virus pre-S/S gene with the sW172* mutation.
 PMID: 27918551       2016       Oncogenesis
Abstract: Hepatitis B virus (HBV) carrying the rtA181T/sW172* mutation conferred cross-resistance to adefovir and lamivudine.
Introduction: Clinical analysis showed that the rtA181T/sW
Discussion: The rtA181T/sW172* mutant exerts cross-resistance to both lamivudine and adeforvir.


  Pre-existing mutations related to tenofovir in chronic hepatitis B patients with long-term nucleos(t)ide analogue drugs treatment by ultra-deep pyrosequencing.
 PMID: 27602500       2016       Oncotarget
Result: A wave of resistantance-associated variants was detected at 3 year, as the frequency of the rtA181T substitution rose from 1.91% to 54.23%.
Result: All treatment-naive patients carried rtA181V/T substitutions (ranging from 1.1% to 8.7%) and rtN236T substitutions (ranging from 1.4% to 6.1%).
Result: As shown in Figure 8B, this patient harbored the rtA181T (1.3%) and rtN236T (1.6%) substitutions at baseline, and other resistance mutations were present at low levels (<1%).

Browser Board

 Co-occurred Entities




   Filtrator